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The prevalence of mutant isocitrate dehydrogenase 1 (IDH1) brain tumors has 
generated significant efforts to understand the role of the mutated enzyme product 
d-2-hydroxyglutarate (D2HG), an oncometabolite, in tumorigenesis, as well as means 
to eliminate it. Glymphatic clearance was proposed as a pathway that could be manip-
ulated to accelerate D2HG clearance and dictated the study design that consisted of 
two cohorts of mice bearing U87/mutant IDH1 intracerebral tumors that underwent two 
microdialysis – providing D2HG interstitial fluid concentrations – sampling periods of 
awake and asleep (activate glymphatic clearance) in a crossover manner. Glymphatic 
clearance was found not to have a significant effect on D2HG brain tumor interstitial 
fluid concentrations that were 126.9 ± 74.8 μM awake and 117.6 ± 98.6 μM asleep. 
These concentrations, although low relative to total brain tumor concentrations of 
6.8 ± 3.6 mM, were considered sufficient to be transported by interstitial fluid and taken 
up into normal cells to cause deleterious effects. A model of D2HG CNS distribution 
supported this contention and was further supported by in vitro studies that showed 
D2HG could interfere with immune cell function. The study provides insight into the 
compartmental distribution of D2HG in the brain, wherein the interstitial fluid serves as 
a dynamic pathway for D2HG to enter normal cells and contribute to tumorigenesis.
Keywords: oncometabolite brain distribution, immune function, transport model, glymphatic clearance, brain 
microdialysis
inTrODUcTiOn
The identification of isocitrate dehydrogenase 1 (IDH1) gene mutations in more than 70% of low 
grade astrocytomas and oligodendrogliomas as well as secondary glioblastomas (GBMs) (1, 2) has 
led to a significant drive to develop diagnostic and treatment modalities able to exploit this mutation 
for therapeutic gain. The most common mutation, the heterozygous substitution of a guanine for 
an adenine nucleobase at codon 395 (G395A), results in an R132H mutation in the active site of 
IDH1 (3). This mutation results in a heterodimer containing wild-type and mutant IDH1 (mIDH1) 
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subunits, allowing for both the oxidative decarboxylation of 
isocitrate to α-ketoglutarate (KG) and the reduction of KG to 
d-2-hydroxyglutarate (D2HG), an oncometabolite (4).
D2HG has been shown to accumulate in patient-derived 
tumors in millimolar concentrations (4); however, its precise 
biological role is the subject of ongoing investigations. It is impli-
cated in methylome reprogramming – both DNA and histones – 
of cancers by inhibiting histone demethylases and the TET family 
of hydrolases resulting in the CpG island methylator phenotype 
(G-CIMP) (5–7). The enantiomer of D2HG, l-2-hydroxyglutarate 
(L2HG), has been shown to be a more potent inhibitor of the 
KG-dependent dioxygenases (8, 9), and its increased production 
has been correlated with hypoxic tumor microenvironments 
(10, 11). Both enantiomers are present in bodily fluids as a by-
product of metabolism, but their concentrations are regulated 
by stereospecific dehydrogenase enzymes capable of oxidation 
back to KG (12, 13). The high concentrations of D2HG in brain 
tumors and the aforementioned biological actions of this neo-
morphic metabolite are implicated in tumorigenesis, although 
the potential effects on normal cells, including those involved in 
immunological responses remain to be defined.
The high concentrations of D2HG produced in mIDH1 
brain tumors overcome detoxification by d-2-hydroxyglutarate 
dehydrogenase (D2HGDH), and thus, other avenues to mini-
mize D2HG are avidly being pursued. First and foremost are 
the use of mIDH1 enzyme inhibitors, such as AG120 or AG881, 
that are currently being evaluated in the clinic for advanced 
hematologic cancers, including acute myeloid leukemia, as well 
as GBMs (2, 14, 15). The glymphatic system, a newly discov-
ered mechanism of CNS clearance for proteins associated with 
neurodegenerative diseases (16), may be an alternate means 
to accelerate D2HG elimination from the brain. This system, 
which is tightly regulated by sleep/wake cycles and aquaporin-4 
expression, was shown to increase β-amyloid clearance through 
pharmacological means – both anesthesia and an adrenergic 
receptor blocking cocktail – that simulate sleep (17). Since very 
little is known about the brain disposition of D2HG, including 
its potential as a biomarker, its role in tumorigenesis, and its 
propensity for glymphatic clearance, we monitored D2HG and 
L2HG concentrations in brain tumor interstitial fluid (BTIF) by 
performing microdialysis in both awake and anesthetized mice 
bearing intracerebral mIDH1 tumors.
MaTerials anD MeThODs
chemicals and reagents
All chemicals and reagents were purchased from commercial 
sources and used without further purification. L2HG disodium 
salt and (+)-O,O′-diacetyl-l-tartaric anhydride (DATAN) were 
obtained from Sigma-Aldrich (St. Louis, MO, USA). D2HG 
disodium salt and dl-2-hydroxyglutaric acid-d3 (dl-2HG-d3) 
disodium salt were obtained from Cayman Chemical (Ann 
Arbor, MI, USA) and Toronto Research Chemicals (Toronto, ON, 
Canada), respectively. Guide cannulas and microdialysis probes 
(Meta-Quant) were purchased from Brainlink B.V. (Groningen, 
Netherlands). Mass spectrometry-grade chemicals and solvents 
were obtained from Fisher Scientific (Fair Lawn, NJ, USA) or 
Sigma-Aldrich (St. Louis, MO, USA). All other chemicals and 
materials were obtained from commercial suppliers.
animals and cell lines
Male NCr nude mice (nu/nu, 4 weeks old) were purchased from 
Taconic Farms (Germantown, NY, USA). All animal experi-
ments were approved by the Institutional Animal Care and Use 
Committee according to the National Institutes of Health guide-
lines. U87 cells that had been stably transfected with the R132H 
IDH1 mutation were kindly provided by Agios Pharmaceuticals 
(Dr. Michael Su, Cambridge, MA, USA), and used as previ-
ously described (4). R132H_mIDH1/U87 cells were grown as 
a monolayer in Dulbecco’s modified Eagle’s medium with 10% 
fetal bovine serum, 1× penicillin and streptomycin, and 300 μg/
mL of G418 selection antibiotic and maintained in a humidified 
atmosphere of 5% CO2 in air at 37°C.
Tumor implantation
Male NCr nude mice (5  weeks old) were anesthetized using 
an intraperitoneal dose (0.1  mL/10  g body weight) of 10% 
 ketamine hydrochloride (100 mg/mL) and 8% xylazine (20 mg/
mL) in water and placed in a stereotaxic frame. Tumor cells 
were prepared fresh from culture and kept in suspension 
(1  ×  105  cells/μL in phosphate-buffered saline) on ice until 
implantation. Each mouse had 3  μL of suspension injected 
(3 ×  105 tumor cells) into the right caudate putamen (0.7  mm 
anterior and 2.2  mm lateral from the bregma) at a depth of 
2.5  mm. The injection site on the skull was sealed with sterile 
bone wax, and the incision was closed and fixed with wound glue. 
Mice received a standard mouse diet and water ad  libitum and 
received 3 days of post-operative analgesic care that consisted of 
a daily 5-mg/kg subcutaneous dose of carprofen. Animals were 
weighed, assessed for body condition score, and monitored for 
neurological symptoms daily.
guide cannula implantation
Thirteen days after tumor implantation (corresponding to at 
least 7  days before the microdialysis studies), guide cannulas 
were implanted. Mice were again anesthetized and placed in the 
stereotaxic frame in the same manner as above. Incision sites 
from the first surgery were opened, and the injection site located 
on the skull. A guide cannula was implanted at the injection site 
and secured with two anchor screws and dental cement. Mice 
were then individually housed for the duration of the study and 
received a standard mouse diet and water ad libitum and received 
3 days of post-operative analgesic care that consisted of a daily 
5-mg/kg subcutaneous dose of carprofen. Animals were weighed, 
assessed for body condition score, and monitored for neurologi-
cal symptoms daily.
Brain Microdialysis
Microdialysis studies were completed 20–23 days after glioma cell 
implantation. This generally coincided with either a 20% loss in 
body weight, the first sign of neurological symptoms, or an obser-
vation of a body condition score of 2 or lower. For microdialysis, 
a harness was secured around the mouse’s torso, and the dummy 
probe from the guide cannula was removed and replaced with a 
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brain microdialysis probe that contains two inlets; one referred 
to as the make-up flow rate and the other the low flow rate inlet 
that perfused the dialysis membrane. The probes were perfused 
at a total flow rate of 1 μL/min (both inlets initially at 0.5 μL/
min from each pump) for at least 20 min with sterile water and 
artificial cerebrospinal fluid (147 mM NaCl, 2.7 mM KCl, 1.2 mM 
CaCl2, and 0.85 mM MgCl2). Flow rates were then adjusted as the 
probes were continued to be perfused for an additional 40 min 
at 0.9 μL/min with sterile water from the make-up pump and 
0.1 μL/min with artificial cerebrospinal fluid from the low flow 
rate pump. After this equilibration period, the study commenced 
with brain microdialysis samples collected in 20-min intervals 
into a CMA (Harvard Apparatus, Holliston, MA, USA) 470 
fraction collector that maintained the samples at 4–6°C for the 
duration of the study. Samples were transferred to sterile 200 μL 
polypropylene tubes after collection and stored at −80°C until 
they were analyzed.
Mice were randomly separated into the awake–asleep and 
asleep–awake cohorts. Mice that were awake first had brain 
microdialysis performed for 2 h, then were placed under anes-
thesia (1 L/min O2, 2.5% isoflurane for induction, 1 L/min O2, 
1% isoflurane for maintenance). Sampling continued for an 
additional 2 h. Mice that were under anesthesia first were placed 
under anesthesia (same as in the other cohort), but immediately 
after the equilibration period of the probe. After a 2-h asleep 
period, the anesthesia was stopped, and a 1-h recovery period 
commenced prior to a 2-h awake sampling period. All mice 
regained consciousness by the end of the recovery period. At 
the conclusion of microdialysis, brain, tumor, and plasma were 
collected.
Plasma collection
At the conclusion of brain microdialysis, with mice under heavy 
anesthesia (1 L/min O2, 2.5% isoflurane), cardiac puncture was 
performed to obtain a whole blood sample using a 1-mL syringe 
and 23-G needle. Total recovered volume was immediately 
injected into a K2EDTA-coated tube. The tube was inverted at 
least 12 times to ensure that all of the blood was exposed to anti-
coagulant, and then the sample was stored on ice until processing. 
The mouse was euthanized by cervical dislocation while under 
isoflurane anesthesia. Whole blood with anticoagulant was trans-
ferred to a 1.5- or 0.5-mL microcentrifuge tube as appropriate 
and centrifuged at 3000  rpm and 4°C for 15 min. Supernatant 
(plasma) was carefully removed from tube while leaving pel-
let and Buffy coat undisturbed and transferred to new 0.5-mL 
Eppendorf tubes in 100 μL aliquots, labeled, and stored at −80°C 
until analyzed.
Brain and Tumor homogenization
Whole brain and tumor were harvested from each mouse. 
Indentation of the microdialysis probe was checked to ensure 
proper sampling location in the tumor. Brain and tumor samples 
were separated into three sections: tumor, brain (ipsilateral to 
tumor), and brain (contralateral to tumor). Sections were rinsed 
with ice cold sterile water and stored on ice until they were weighed. 
Each section was transferred to a sample tube to be weighed. For 
every gram of tissue present, 5 mL of ice cold sterile water was 
added, resulting in a final concentration of 200  mg tissue/mL. 
Homogenization was performed using a PolyTron PT 2100 tis-
sue homogenizer set to 30,000 rpm for 5 s. The homogenizer was 
cleaned before and after each tissue sample. Homogenates were 
transferred to labeled 1.5-mL microcentrifuge tubes and stored at 
−80°C until ready to be analyzed.
Derivatization and sample Preparation
Microdialysis Samples
A 5-μL aliquot of microdialysate was added to a screw-top glass 
GCMS vial containing 5 ng of dl-2HG-d3 internal standard in 
MeOH. The samples were vortexed and dried under a stream 
of nitrogen at 30°C. The samples were derivatized with DATAN 
according to a previously published procedure (18). The derivat-
ized samples were resuspended in 50 μL of milli-Q water and 
analyzed by LC-MS/MS.
Plasma, Tumor Homogenate, and Brain 
Homogenates
Plasma samples were diluted 1:1 in milli-Q water. Tumor and 
brain homogenate samples were diluted to a final volume of 4 
and 100 mg/mL, respectively, with milli-Q water. An 8-μL aliquot 
of diluted plasma, brain homogenate, or tumor homogenate was 
added to 32 μL of ice cold MeOH containing 75 ng/mL dl-2HG-
d3 internal standard. The sample was vortexed and centrifuged at 
14,000 × g for 10 min at 4°C. A 25-μL aliquot of the supernatant 
was added to a screw-top glass GCMS vial, evaporated under a 
stream of nitrogen gas, and derivatized as above. The derivatized 
sample was resuspended in 50 μL of milli-Q water and analyzed 
by LC-MS/MS.
Instrumentation and LC Parameters
Liquid chromatography–mass spectrometry was performed on 
a QTRAP 5500 triple quadrupole mass spectrometrer (SCIEX, 
Framingham, MA, USA) equipped with a Shimadzu Prominence 
UFLC liquid chromatography system (Shimadzu, Kyoto, Japan). 
A 5 μL of sample was injected onto a Luna C18(2) 50 mm × 2 mm, 
3 μm column (Phenomenex, Torrance, CA, USA) and chroma-
tographic separation occurred in water with 5 mM ammonium 
formate adjusted to pH 3.15 ±  0.05 with formic acid and 5% 
MeOH mixed online with a flow rate of 200 μL/min. The first 
4  min of post-column eluent containing excess DATAN was 
diverted to waste to avoid contamination of the mass spectrom-
eter source. After 4  min of chromatographic separation, post 
column eluent was introduced by electrospray ionization (ESI) 
into the mass spectrometer and monitored by multiple reaction 
monitoring (MRM) in negative ionization mode. Compound 
and instrument-dependent parameters were optimized for each 
compound of interest (see Supplementary Material).
Quantification of 2HG
For quantification of D2HG and L2HG in microdialysis samples, a 
standard curve from 20 to 10,000 ng/mL of D2HG and L2HG was 
created in CNS perfusion fluid and derivatized as above. Plasma, 
brain homogenates, and tumor homogenates were quantified 
using the isotope dilution method with standard curves in milli-
Q water containing 20–300, 100–10,000, or 20–10,000  ng/mL 
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D2HG and L2HG for plasma, tumor homogenates, and brain 
homogenates, respectively. The MRM transitions monitored were 
363 → 147 for D2HG and L2HG and 366 → 150 for dl-2HG-d3 
in microdialysis samples. Due to matrix interference, an MRM 
of 363 →  129 was used for L2HG in plasma and an MRM of 
366 → 131 was used for dl-2HG-d3 in plasma, brain, and tumor 
homogenate samples. Data were processed and standards were fit 
to a 1/×-weighted linear regression using Analyst 1.6.2. Intraday 
and interday (n = 3) validation was performed for all matrices 
will replicates (n = 5) of low, medium, and high quality control 
standards (see Supplementary Material).
Brain Distribution Model of D2hg
The compartmental model used for D2HG simulations 
specifies three subcompartments – intracellular interstitial fluid 
and CSF – for both the glioma and normal cell compartments 
(see Results). This is consistent with the physiologically based 
pharmacokinetic models of tissue distribution of intracellular, 
interstitial fluid, and vascular subcompartments; however, a 
brain vascular compartment was not considered as an important 
aspect of the current model for D2HG since plasma concentra-
tions are minimal, about 1 μM, and would not recycle across 
the blood–brain barrier in significant amounts. The model only 
considers the two most relevant cell spaces; the glioma cells and 
those normal cells in close proximity that would most likely be 
exposed to D2HG in the adjacent interstitial fluid compartment. 
The model also includes a terminal CSF compartment that rep-
resents the subarachnoid spaces that do not exchange material 
with the brain interstitial fluid compartments (19, 20). The model 
differential equations and parameters are provided in Table S5 in 
Supplementary Material. Physiological volumes were calculated 
from standard relationships based on an average measured tumor 
weight of 100 mg and assuming a density of 1 g/mL. The CSF 
bulk flow rate was taken from the literature (21), and the brain 
interstitial fluid flow (6.0 × 10−7 L/h) was an intermediate value 
in the range of 0.15–0.29 μL/min/g estimated in rats (22). Other 
than the influx rate of D2HG into the intracellular compartments, 
which was considered to be non-linear, all intercompartmental 
clearances and the systemic clearance from plasma are consid-
ered to be linear or concentration independent. The non-linear 
intracellular influx was represented as a Michaelis–Menten trans-
port process based on the likely mechanism that NaDC3 is a key 
dicarboxylic acid transporter (23, 24). The model rate equations 
and parameters are provided in the Supplemental Material.
culture of human T cells, intracellular 
staining, and Flow cytometric analysis
Peripheral blood (PB) from de-identified healthy donors was col-
lected in this study after obtaining informed consent. This study 
was approved by the IRB committee of Temple University. Naïve 
CD4+ T cells and CD8+ T cells were obtained from PB mono-
nuclear cells (PBMCs) through negative selection using human 
naïve T cell isolation kit II from Miltenyi Biotec (San Diego, CA, 
USA). T cells were activated by anti-CD3 Ab + anti-CD28 Ab at 
day 0. D2HG – ranging from 0 to 500 μM concentrations – was 
added to the culture on day 0. Cells were collected at different time 
points of culture, counted, and analyzed for intracellular staining 
of IFN-γ using an intracellular staining kit from BD (BD Cytofix/
Cytoperm™ Kit, BD Biosciences, CA, USA) and antibodies from 
Biolegend. Multi-color flow cytometric analysis was performed 
using a BD LSRII flow cytometer as described (25).
resUlTs
D2hg is Present in Micromolar 
concentrations in Tumor interstitial Fluid
There were two cohorts of nine mice each studied in a crossover 
fashion with either an awake–asleep cycle or an asleep–awake 
cycle. Each awake and asleep study period was of a 2-h duration 
– 6 microdialysis samples – that included an equilibration period 
of 1-h prior to the start of the study and a 1-h re-equilibration 
period in the asleep–awake cohort to ensure the mice were fully 
conscious prior to the 2-h awake period sample collection. The 
concentrations of both D2HG and L2HG were monitored in 
BTIF by microdialysis in mice bearing intracerebral mIDH1/U87 
brain tumors. Concentrations of L2HG were found to be under 
the lower limit of quantitation (1.35  μM) in all microdialysis 
samples collected. D2HG concentrations were measured in all 
microdialysis samples from each of the 18 mice (Figures 1A,B), 
wherein it can be seen that BTIF concentrations varied consider-
ably between the mice with a mean ± SD of 122.3 ± 84.2 μM for 
all mice included in the study.
In order to analyze the D2HG BTIF concentrations, we 
defined a steady-state period to be the longest consecutive time 
period (a minimum of three samples or a 1-h period) of measured 
concentrations with a CV ≤ 25%. All 18 mice contained segments 
in both the awake and asleep states that fulfilled the steady-state 
inclusion criteria (Figure  2; Table  1). There was no sequence 
effect observed between the two cohorts (p =  0.98), indicative 
that the timing of anesthesia did not have an effect on the D2HG 
concentrations in the two states. Thus, there were a total of 36 
study periods – 18 awake and 18 asleep – that produced mean 
D2HG BTIF concentrations in the asleep state of 117.6 versus 
126.9 μM in the awake state.
concentration of D2hg Found in 
Brain Tumor homogenate
Table 1 shows the concentrations of D2HG in total brain tumor 
homogenates, wherein it can be seen the values were in the mil-
limolar range (assuming a tumor density of 1.00 g/mL), which 
is consistent with previous studies analyzing D2HG levels in 
R132H_mIDH1/U87 tumors (4, 26). The mean D2HG brain 
tumor concentration for all mice was 6.8 ± 3.6 mM, with a range 
from ~500 μM to >10 mM. No tumors contained quantifiable 
L2HG (LLOQ = 170 μM). The concentrations of D2HG in BTIF 
ranged from 0.5 to 7.6% (average =  2.4%) of the total tumor 
concentrations, and thus, quite variable between mice (Table 1). 
The tumor D2HG concentrations did not vary significantly 
between cohorts (p =  0.76), indicative that anesthesia did not 
impact the overall D2HG concentration in the tumors. The 
inter-animal variability in D2HG BTIF and tumor concentra-
tions is likely due to the inherent heterogeneity of the tumors 
caused by regions of necrosis and proliferation that would affect 
FigUre 1 | D2hg brain tumor interstitial fluid concentrations in miDh1/U87 tumor-bearing mice in two sequenced cohorts. Awake–asleep (a) and 
asleep–awake (B). Each line is representative of one mouse.
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the number of viable cells producing D2HG. In addition, the 
tumor homogenate concentrations reflect distribution into 
normal cells and its subpopulations that may be subjected to 
differential distribution. Finally, the heterogeneity is dependent 
on the actual collected sample; mIDH1/U87 tumors are well 
demarcated, so gross dissection to yield a tumor sample is not 
likely to introduce large errors; however, microdialysis sampling 
is dependent on the tumor environment and the restrictions 
imposed by the spatial resolution of microdialysis probe (27). 
Previous studies utilizing U87MG orthotopic xenograft models 
have displayed a heterogenous population of tumor cell types 
(28) as well as variable metabolic profiles among various tumor 
cells, usually correlated with hypoxic versus normoxic regions 
of tumors (29, 30).
concentrations in ipsilateral/contralateral 
Brain and Plasma
The concentrations of D2HG were quantifiable (≥1.35 μM) in 
all non-brain tumor samples. The concentrations (assuming 
a density of brain tissue of 1.00 g/mL) of D2HG in ipsilateral 
and contralateral brain ranged from 4.2 μM to 2 mM and 3.0 
to 48.6 μM, respectively (Table S4 in Supplementary Material). 
In contrast, the L2HG levels in ipsilateral and contralateral 
brain ranged from 1.35 to 10.63  μM and 1.35 to 14.65  μM, 
respectively; however, concentrations in four ipsilateral and 
three contralateral brain samples were less than the lower limit 
of quantitation (1.35 μM).
Plasma samples collected from each mouse (excluding mouse 
10, for which a usable sample volume could not be obtained) 
contained both isomers of 2HG in quantifiable concentrations 
(≥0.27  μM). The plasma concentrations of D2HG (Figure  2; 
Table S4 in Supplementary Material) and L2HG ranged from 0.36 
to 3.48 μM and 0.41 to 1.44 μM, respectively. Although plasma 
D2HG concentrations were very low compared with tumor 
concentrations, there was a strong positive correlation observed 
between them (r = 0.78, p < 0.001), suggesting that tumor D2HG 
distributes from the CNS into the systemic circulation.
implications of D2hg Distribution  
in Brain Tumors
The high D2HG concentrations in total tumor homogenate 
bated the question of the cellular localization of D2HG. 
It  was surmised that the high concentrations were not likely 
confined to glioma cells and might accumulate in normal 
FigUre 2 | comparison of D2hg concentrations in microdialysate, tumor homogenate, and plasma. Tumor homogenate concentrations were calculated 
assuming a tissue density of 1.00 mg/mL. Microdialysate values represent the average of the awake and asleep states after statistical analysis to determine 
steady-state segments in each period.
TaBle 1 | concentrations of D2hg in BTiF (steady-state) and brain tumor.
cohort Mouse #
D2hg in BTiF (μM)
D2hg in  
tumor (μM)
average  
BTiF/tumor 
(%)awake asleep average % change
Awake–asleep 1 194.6 139.1 166.8 −28.5 2912 5.7
2 131.4 106.5 118.9 −18.9 1755 6.8
3 39.4 32.5 36.0 −17.5 473 7.6
4 133.4 119.6 126.5 −10.3 10,752 1.2
5 179.3 128.8 154.1 −28.2 9427 1.6
6 76.9 102.1 89.5 32.7 10,558 0.8
7 56.0 29.5 42.7 −47.4 5832 0.7
8 149.6 112.1 130.9 −25.1 8659 1.5
9 246.7 234.7 240.7 −4.9 8473 2.8
Asleep−–awake 10 267.4 369.7 318.6 38.2 8043 4.0
11 120.9 42.6 81.8 −64.8 9756 0.8
12 132.7 71.8 102.3 −45.9 10,254 1.0
13 104.1 79 91.5 −24.1 4076 2.2
14 6.2 6.4 6.3 3.0 1256 0.5
15 57.0 42.7 49.9 −25.1 6870 0.7
16 25.2 30.3 27.7 20.2 3190 0.9
17 208.4 304 256.2 45.9 9402 2.7
18 155.2 165.9 160.5 6.9 10,845 1.5
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cells, particularly those in the adjacent microenvironment, 
using interstitial fluid as a conduit for cell-to-cell transfer. 
This general phenomenon has been considered previously 
(22), and within the guise of D2HG being tumorigenic, it 
is fair to assume its uptake into normal glial or precursor 
cells and cells needed for an immune response could be a 
contributing factor. A semi-mechanistic model of D2HG 
was developed (Figure  3A, see Materials and Methods) that 
consisted of an eight-compartment model with intracellular, 
interstitial fluid, and CSF compartments for both the glioma 
and normal cell compartments. The model parameters included 
physiological volumes and brain interstitial and CSF fluid flow 
rates with the remaining transport parameters calibrated to 
the observed D2HG concentrations in the brain tumor, BTIF, 
and plasma; being about 6000, 125, and 1.5 μM, respectively. 
The total tumor homogenate D2HG concentration represents 
an intracellular glioma cell compartment concentration of 
10,000 μM (see Materials and Methods). The model assumed 
linear intercompartmental transfer of D2HG except for the 
influx from interstitial fluid – both in the glioma and normal 
cell compartments – to the intracellular compartment where 
Michaelis–Menten transport was assumed based on the likeli-
hood D2HG was a substrate for NaDC3 (SLC13A3) (23, 24). 
The simulations show (Figure  3B) that appreciable D2HG 
concentrations – 9400  μM – may be attained at steady state 
in the adjacent normal cell intracellular compartment or 93% 
of those attained in the glioma intracellular compartment. It 
can be seen that there is a time lag for each compartment 
to achieve steady-state D2HG concentrations consistent with 
a concentration gradient from the glioma interstitial fluid 
compartment to the normal cell interstitial fluid compartment 
due to the convective flux of D2HG once it exits glioma cells 
Plasma
HGp
HGicGli HGicNor
HGifGli HGifNor
HGcsfmGli HGcsfmNor HGcsfT
A
B
FigUre 3 | Brain distribution model for D2hg. (a) Model of D2HG (HG in figure) brain distribution. Each compartment is assumed to be homogeneous with 
respect to D2HG concentrations. Compartments (subscripts): icGli, intracellular glioma cells; icNor, intracellular normal cells; ifGli, interstitial fluid glioma; ifNor, 
interstitial fluid normal; csfmGli, main CSF glioma; csfmNor, main CSF normal; csfT, terminal CSF; p, plasma. Black arrows represent linear intercompartmental 
clearances, solid red arrows represent Michaelis–Menten influx via NaDC3 transporter, hatched red arrow represents zero-order production rate of D2HG. 
(B) Simulated D2HG concentrations in glioma and normal cell compartments using brain distribution model. Please note different y-axes scales. Abbreviations in 
the legends are the same as in (a). Model equations and parameter values (Table S5 in Supplementary Material) are provided in Supplementary Material.
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FigUre 4 | D2hg reduces proliferation of human T cells cultured in vitro. Human CD4 and CD8 T cells were activated by anti-CD3 Ab + anti-CD28 Ab at 
day 0. A range of D2HG concentrations was added to the culture on day 0. (a) At the indicated time points, the number of T cells in the culture was counted, 
calculated for the recovery rate based on the following formula: fold change of recovery rate = output cell number/input cell number. (B) Cells were collected at day 
12 for intracellular staining of IFN-γ and flow cytometry analysis (*p < 0.05).
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into the interstitial fluid space. As a simulation exercise there 
is uncertainty in the parameter values and other parameter 
sets provide analogous simulated results; nonetheless, the 
results support the feasibility that high D2HG concentrations 
in glioma cells permit flux into the interstitial fluid compart-
ment for transfer into normal cells. This possibility prompted 
an investigation of D2HG action on immune cells, both CD4 
and CD8 T-cells.
D2hg action on immune cells
To test the possible action of D2HG on immune cells, we exam-
ined the effect of D2HG on the proliferation and IFN-γ by human 
T cells that were activated by anti-CD3 antibody (Ab) and anti-
CD28 Ab. Addition of D2HG caused a significant decrease (two-
fold to threefold) in expansion of these activated CD4+ and CD8+ 
T cells in a dose-dependent manner (Figure 4A). Interestingly, 
treatment with 500 μM D2HG enhanced the production of IFN-
γ-producing T cells in cultures compared with untreated controls 
(Figure 4B). These results suggest that glioma cell-derived D2HG 
may interfere with T cell immune function.
DiscUssiOn
Patients with mutant IDH1 brain tumors are prevalent with 
a number of investigations describing the biological and 
biochemical effects of the oncometabolite, D2HG, which is 
produced in high quantities. Among the panoply of D2HG 
actions are its ability to inhibit KG-dependent enzymes and to 
remodel the methylome creating the G-CIMP phenotype (7). 
The consequences of these effects are unanswered as are ques-
tions related to the brain disposition of D2HG and whether 
its compartmentalization in the brain and brain tumor might 
suggest how it may be involved with tumorigenesis and whether 
alternate and companion treatments to mutant IDH1 inhibitors 
could play a role.
This investigation provides the first direct evidence that D2HG 
exits glioma cells and is present in the interstitial fluid compart-
ment at micromolar concentrations. The D2HG concentrations 
are a small fraction of those measured in total tumor homogen-
ates, and on face value suggests that therapeutic modalities 
directed at BTIF D2HG may be unwarranted. One BTIF-directed 
9Pickard et al. D2HG in Brain Tumor Interstitial Fluid
Frontiers in Oncology | www.frontiersin.org October 2016 | Volume 6 | Article 211
approach – glymphatic clearance activation – produced an aver-
age 7% reduction in D2HG steady-state concentrations under 
anesthesia, and even though one could envision that pharmaco-
logical means to accelerate glymphatic clearance over a longer 
duration could be more effective than the 2-h asleep periods 
evaluated here it is not likely to materialize into a major effect. 
Nonetheless, there are other scenarios where BTIF-directed 
therapy may be effective and could be combined with mIDH1 
inhibitors. The BTIF D2HG concentrations provide a pathway 
for D2HG to enter normal cells and contribute to tumorigenesis. 
Of the normal cell types that D2HG could adversely affect are 
cells involved in the immune response, both T-cells and dendritic 
cells. For D2HG to be effectively taken up into normal cells, such 
as T-cells, there are likely one or more membrane transport 
systems. As a dicarboxylic acid it is likely D2HG is a substrate 
for SLC family members that transport KG, and in fact, D2HG 
was a substrate of NaDC3 (SLC133A) (Km = 164 ± 14 μM) in 
oocytes that overexpressed it (31). Additional studies in cell 
systems and including other carrier proteins seem warranted. 
These membrane transport proteins function in either mono- 
or bi-directional capacities and could be an alternate target to 
prevent cell uptake. Thus, one hypothesis is D2HG is effluxed 
from glioma cells into BTIF space, wherein it is available to enter 
normal cells via NaDC3 or other carriers and accumulate to 
high concentrations. To test the feasibility of this hypothesis, we 
developed a model for D2HG (Figure 3A) brain disposition that 
consisted of intracellular, interstitial fluid, and CSF glioma and 
normal cell compartments connected via bulk flow of interstitial 
fluid. The simulated results – although not confirmed – indicate 
appreciable D2HG distribution into the normal cell intracellular 
compartment. This observation raises the specter of how D2HG 
exerts its tumorigenic action and supports studies to dissect its 
action in specific cell types rather than whole tumor homogenate 
analyses.
Given the high relevance of immune function in cancer, we 
considered immune cells as possible normal cell recipients of 
D2HG. Recent studies have demonstrated that the tumor micro-
environment critically influences antitumor activity of T cells. 
Tumor cells may deplete nutrients essential for T cell survival and 
expansion, leading to impaired T cell immunity against tumor 
(32). Our findings suggest another important mechanism by which 
tumors may reduce anti-tumor immunity. Glioma cells produce 
high levels of D2HG that permeate the local environment and 
cause significant reduction of T cell expansion and persistence, 
impairing antitumor effect of these T cells. In addition, some 
studies have demonstrated that although IFN-γ is important for 
T cell-mediated antitumor immunity (33), it also causes increased 
tumor cell expression of PD-L1, which is an immune-check point 
inhibitor. It is possible that increased production of IFN-γ by 
glioma cell-derived D2HG might contribute to the upregulation 
of PD-L1 in tumors, thereby further impairing T cell antitumor 
activity. Thus, our findings indicate that inhibition of D2HG – 
although generally sought – may represent a new strategy to 
improve tumor immunotherapy.
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